A New Weapon in the War on Cancer-And a Rare Early Opportunity

This emerging biotech's patented platform could redefine how cancer is treated-boosting performance while reducing toxicity.

With early momentum and rising Big Pharma interest, this could be one of 2025's most intriguing early-stage plays.

Uncover the Company before Wall Street does

Notice: Please understand that by opting out from future emails from this advertiser, you are transferring or
authorizing the transfer of your email address to the advertiser listed above. Zacks has no control over how
your email address is used by the advertiser or other third parties. Accordingly, Zacks disclaims all
responsibility and liability arising from the subsequent use of your email address that is made possible by
your submission of your email address above. You are receiving this email from Zacks Investment Research
because you chose to receive messages from Zacks’ partners on the Zacks web site(s). Please note that
Zacks does not produce or endorse this product, and assumes no responsibility for the use thereof.

Your privacy is important to us. Click here to see our Privacy Policy: https://www.zacks.com/privacy.php
If you do not wish to receive further email solicitations from Zacks on behalf of its partners, please click here
to unsubscribe.

Zacks Investment Research
10 S. Riverside Plaza, Suite 1600
Chicago, IL 60606